fig2
Figure 2. Overall and progression-free survival for ICI alone or plus lenvatinib in the second-line treatment of EC. ICI: Immune checkpoint inhibitor; EC: endometrial cancer.
Cancer Drug Resistance
ISSN 2578-532X (Online)
Navigation
Navigation
Committee on Publication Ethics
https://members.publicationethics.org/members/cancer-drug-resistance
Portico
All published articles will preserved here permanently:
https://www.portico.org/publishers/oae/
